Henan Cancer Hospital clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 1 with a minor change only.

1. Notable

   ARX788 in HER2-positive Metastatic Breast Cancer Patients

   Primary completion pushed from Nov 20, 2025 to Nov 20, 2027

   Also in this update: Recruitment opened

   Henan Cancer Hospital·Phase 2· NCT06663748· Registry history of NCT06663748 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Notable

   Ⅱ Clinical Study of Utidelone Combined With Capecitabine · Active…Ⅱ Clinical Study of Utidelone Combined With Capecitabine · Active Brain Metastasis of TNBC

   Primary completion pushed from Jun 1, 2026 to Jun 1, 2028

   Also in this update: Trial status changed: Unknown → Recruiting; Study completion pushed from Aug 1, 2026 to Aug 1, 2028

   Henan Cancer Hospital·Phase 2· NCT06598046· Registry history of NCT06598046 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

3. Notable

   SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

   Enrollment reduced: 60 → 30 participants

   Also in this update: Recruitment opened; Interventions modified

   Henan Cancer Hospital·Phase 2· NCT07125950· Registry history of NCT07125950 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.